GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lepu Biopharma Co Ltd (HKSE:02157) » Definitions » Current Accrued Expense

Lepu Biopharma Co (HKSE:02157) Current Accrued Expense : HK$0.0 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lepu Biopharma Co Current Accrued Expense?

Lepu Biopharma Co's Current Accrued Expense for the quarter that ended in Dec. 2024 was HK$0.0 Mil.


Lepu Biopharma Co Current Accrued Expense Historical Data

The historical data trend for Lepu Biopharma Co's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lepu Biopharma Co Current Accrued Expense Chart

Lepu Biopharma Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
Get a 7-Day Free Trial - - - - -

Lepu Biopharma Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lepu Biopharma Co Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Lepu Biopharma Co Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Lepu Biopharma Co's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Lepu Biopharma Co Business Description

Traded in Other Exchanges
N/A
Address
No. 651, Lianheng Road, Minhang District, Shanghai, CHN, 201612
Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in the PRC. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain.
Executives
Pu Zhongjie 2201 Interest of corporation controlled by you
Hu Chaohong 2201 Interest of corporation controlled by you
Pu Jue 2201 Interest of corporation controlled by you
Hao Chunmei 2202 Interest of your spouse
Su Rongyu 2101 Beneficial owner
Miracogen Inc. 2201 Interest of corporation controlled by you
Miracogen Limited 2101 Beneficial owner
Cereblue Limited 2201 Interest of corporation controlled by you
Bei Jing Hou De Yi Min Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Hou De Yi Min Xin Xi Ke Ji You Xian Gong Si 2101 Beneficial owner
Le Pu Bei Jing Yi Liao Qi Xie Gu Fen You Xian Gong Si 2101 Beneficial owner
Lv Yuan Shang Hai Ke Ji You Xian Gong Si 2101 Beneficial owner

Lepu Biopharma Co Headlines

No Headlines